List of Excipients in Branded Drug TREXIMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Rebel Distributors Corp	TREXIMET	sumatriptan succinate and naproxen sodium	21695-954	ANHYDROUS DIBASIC CALCIUM PHOSPHATE
Rebel Distributors Corp	TREXIMET	sumatriptan succinate and naproxen sodium	21695-954	CARBOXYMETHYLCELLULOSE SODIUM
Rebel Distributors Corp	TREXIMET	sumatriptan succinate and naproxen sodium	21695-954	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	TREXIMET	sumatriptan succinate and naproxen sodium	21695-954	CROSCARMELLOSE SODIUM
Rebel Distributors Corp	TREXIMET	sumatriptan succinate and naproxen sodium	21695-954	DEXTROSE MONOHYDRATE
Rebel Distributors Corp	TREXIMET	sumatriptan succinate and naproxen sodium	21695-954	FD&C BLUE NO. 2

Treximet Excipient Strategy and Commercial Opportunities

Last updated: September 23, 2026

Treximet is a fixed-dose oral combination of sumatriptan succinate and naproxen sodium indicated for acute treatment of migraine with or without aura in adults and, under FDA labeling, patients 12 years and older. Its commercial value comes from combining a triptan with an NSAID in one immediate-release tablet. The principal excipient opportunity is not a new active ingredient. It is improvement in dissolution, tablet size, swallowability, stability, manufacturing efficiency, and dose flexibility while preserving the established 85 mg/500 mg clinical profile.

Treximet has faced generic competition, reducing the value of the legacy branded product. Commercial opportunities remain in generic supply, differentiated oral formulations, pediatric and adherence-focused products, and geographic markets where fixed-dose migraine combinations remain underpenetrated.

What is Treximet and how does its formulation work?

Treximet contains:

Component	Amount per tablet	Function
Sumatriptan, as sumatriptan succinate	85 mg equivalent	Serotonin 5-HT1B/1D receptor agonist
Naproxen sodium	500 mg	Nonsteroidal anti-inflammatory drug
Tablet excipients	Not disclosed by weight in the prescribing information	Binding, disintegration, lubrication, coating, color, and stability

The marketed product is an immediate-release, film-coated tablet. The combination targets two mechanisms associated with migraine: vasoconstrictive and neurogenic effects from sumatriptan, and inflammatory pain pathways inhibited by naproxen.

The formulation challenge is technical. Sumatriptan succinate and naproxen sodium have different physicochemical profiles, dose loads, and release requirements. Naproxen sodium represents most of the tablet mass, while sumatriptan requires reliable content uniformity at a substantially lower dose. The formulation must also prevent delayed disintegration caused by high tablet hardness, hydrophobic lubricants, coating effects, or interactions between the two active pharmaceutical ingredients.

What excipients are used in Treximet?

The FDA-approved labeling identifies the following inactive ingredients for Treximet: croscarmellose sodium, FD&C Blue No. 2 aluminum lake, hypromellose, magnesium stearate, microcrystalline cellulose, povidone, sodium bicarbonate, sodium lauryl sulfate, talc, and titanium dioxide.[1]

Excipient functions in the marketed tablet

Excipient	Likely formulation role
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant
Povidone	Binder and granulation aid
Sodium bicarbonate	Alkalizing agent and possible microenvironmental pH modifier
Sodium lauryl sulfate	Wetting and dissolution aid
Magnesium stearate	Lubricant
Hypromellose	Film-coating polymer
Talc	Anti-sticking and coating aid
Titanium dioxide	Opacifier and pigment
FD&C Blue No. 2 aluminum lake	Tablet colorant

The combination of croscarmellose sodium, sodium lauryl sulfate, and sodium bicarbonate is commercially relevant. These materials can support wetting and disintegration for a high-dose tablet containing a relatively low-dose, highly potent triptan component. The choice of sodium bicarbonate also indicates attention to local pH and dissolution behavior rather than relying only on mechanical disintegration.

The label identifies the qualitative composition, but not the quantitative excipient levels. Exact percentages, processing order, granulation conditions, particle-size controls, and compression parameters may remain outside the public label and can create manufacturing know-how even when composition claims are no longer enforceable.

What excipient strategies can improve Treximet or generic versions?

The most commercially credible strategies are incremental. Each must preserve bioequivalence to the reference product unless the sponsor pursues a different regulatory pathway.

1. Optimize immediate-release dissolution

A generic or reformulated Treximet tablet must release both actives consistently. Useful development levers include:

• Crospovidone or alternative superdisintegrants in place of, or alongside, croscarmellose sodium.
• Sodium lauryl sulfate or another surfactant to improve wetting.
• Controlled sodium bicarbonate levels to manage microenvironmental pH.
• Lower-magnesium-stearate formulations to reduce hydrophobicity.
• Particle-size engineering for naproxen sodium and sumatriptan succinate.
• Separate granulation of the two active ingredients before final blending.

The commercial goal is a robust dissolution profile across pH conditions, compression-force ranges, and storage periods. A formulation that achieves rapid dissolution with fewer process steps may reduce manufacturing cost and improve generic margins.

2. Reduce tablet size

Treximet combines 585 mg of active substances before excipients. Tablet size therefore limits the value of conventional excipient substitution. High-functionality excipients, co-processed cellulose systems, dry binders, and optimized granulation may reduce excipient burden.

A smaller tablet could improve adherence for patients experiencing nausea, vomiting, or dysphagia during migraine episodes. The limitation is that tablet-size reduction cannot materially reduce the mass of the active ingredients without changing dose or dosage form.

3. Improve dose flexibility

The 85 mg/500 mg strength is clinically established but not highly flexible. A manufacturer could pursue:

• Lower naproxen strengths combined with 85 mg sumatriptan.
• Lower sumatriptan strengths combined with 500 mg naproxen.
• Scored tablets where technically feasible.
• Multiple fixed-dose strengths.
• A co-pack containing separate sumatriptan and naproxen units.

Dose flexibility has a regulatory cost. A new strength or ratio requires additional pharmaceutical development and may require clinical bridging, labeling changes, or a new application strategy. A simple ANDA cannot automatically support every clinically attractive ratio.

4. Develop a rapidly disintegrating product

An orally disintegrating tablet, orally dissolving film, or rapidly dispersible tablet could address patients who have difficulty swallowing during migraine attacks. Treximet is a poor candidate for a conventional orally disintegrating tablet because naproxen sodium contributes substantial mass and can produce taste and mouthfeel problems.

Relevant strategies include:

• Taste-masked granules.
• Multiparticulate dosage forms.
• Sublingual or buccal delivery only if exposure and tolerability are demonstrated.
• A low-water, rapidly dispersing tablet with controlled particle size.
• Separate fast-dissolving sumatriptan and conventional naproxen delivery within a single package.

An ODT would likely be a new product rather than a straightforward generic substitution. The sponsor would need to address local tolerability, dose uniformity, mechanical strength, moisture sensitivity, and comparative exposure.

5. Improve stability and supply-chain performance

Naproxen sodium and sumatriptan succinate must remain stable during manufacturing and storage. Excipient and packaging decisions can target:

• Moisture control through low-water excipients.
• Film coatings that limit moisture ingress.
• Desiccant-containing bottles.
• High-barrier blister packaging.
• Reduced exposure to light for colored or coated tablets.
• Lower residual solvent and aldehyde risk in polymeric excipients.

A formulation that tolerates broader temperature and humidity excursions can create value in emerging markets, hospital channels, and mail-order distribution.

What regulatory pathway applies to Treximet generic products?

The standard U.S. generic pathway is an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. An ANDA applicant generally must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.

For Treximet, pharmaceutical equivalence includes the same active ingredients, strengths, dosage form, and route of administration. Inactive ingredients may differ if they do not affect safety, efficacy, or performance. FDA may require justification for changes involving colorants, preservatives, or excipients with known safety or tolerability concerns.[2]

A materially redesigned delivery system may fall outside a conventional ANDA strategy. An NDA under section 505(b)(2) may be more appropriate for a new release profile, a new dosage form, or a clinically differentiated product.

What FDA milestones define Treximet’s regulatory position?

Milestone	Date
FDA approval of Treximet	April 15, 2008
Original sponsor	GlaxoSmithKline
Active ingredients	Sumatriptan succinate and naproxen sodium
Dosage form	Immediate-release film-coated tablet
Reference strength	85 mg/500 mg
Regulatory category	Prescription drug
Generic pathway	ANDA, subject to FDA requirements

The FDA Orange Book lists Treximet as a reference listed drug and identifies patent and exclusivity information applicable to approved products.[3] Product-specific Orange Book data can change as listings are added, delisted, or updated.

When did Treximet lose exclusivity and what is the generic entry risk?

Treximet’s original regulatory exclusivity has expired. Its principal commercial protection now depends on brand recognition, prescribing habits, distribution, payer positioning, and any surviving patent or regulatory rights.

Generic entry risk is high because:

1. The active ingredients are well established.
2. The product is a small-molecule immediate-release tablet.
3. The reference product’s qualitative excipient profile is public.
4. Bioequivalence can be assessed using conventional pharmacokinetic methods.
5. The indication does not require a complex biologic or device platform.

Early generic entrants can compete on acquisition cost and pharmacy substitution. Later entrants may face compressed pricing unless they achieve lower manufacturing costs, reliable supply, or differentiated packaging.

Patent risk is narrower than it was before generic entry. Historical U.S. patent protection associated with Treximet included combination and formulation claims, but the commercial significance of any particular patent depends on its listing status, expiration, pediatric extensions, terminal disclaimers, and litigation history. Current freedom-to-operate analysis must be based on the live Orange Book and issued patent record rather than historical patent references.[3,4]

What formulation patents could protect a new Treximet product?

A new excipient strategy can support patent claims in several areas:

Composition claims

Claims may cover specified ranges of:

• Sumatriptan succinate.
• Naproxen sodium.
• Superdisintegrant.
• Surfactant.
• Alkalizing agent.
• Binder.
• Lubricant.
• Coating polymer.

Broad composition claims are difficult where the reference product and generic formulations are already public. Narrower ranges may be more defensible if they produce a demonstrated dissolution, stability, or bioavailability result.

Process claims

Potential claims may cover:

• Separate granulation of sumatriptan and naproxen.
• Dry granulation under defined compaction conditions.
• Order of excipient addition.
• Lubrication time.
• Compression-force windows.
• Coating conditions.
• Moisture-control processing.

Process claims are commercially useful only if infringement can be detected or if the protected process is difficult to replace.

Performance claims

A sponsor may seek claims tied to:

• Rapid disintegration.
• Dissolution within specified time points.
• Reduced food effect.
• Improved exposure consistency.
• Lower tablet friability.
• Stability under accelerated conditions.

Performance claims need comparative data. A faster dissolution profile alone does not establish a clinical advantage.

Dosage-form claims

Potentially differentiated dosage forms include:

• Orally disintegrating tablets.
• Multiparticulate capsules.
• Bilayer tablets.
• Coated pellets.
• Fixed-dose co-packaged systems.
• Fast-dissolving films.

The strongest commercial position would combine a differentiated dosage form with a clinical or adherence benefit that is difficult to replicate through simple excipient substitution.

What commercial opportunities exist for Treximet excipients?

Generic Treximet manufacturing

The largest near-term opportunity is supplying excipients and formulation services to generic manufacturers. Key materials include microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, sodium bicarbonate, magnesium stearate, hypromellose, and coating pigments.

Supplier differentiation can come from:

• Consistent particle-size distribution.
• Low-moisture grades.
• Direct-compression performance.
• Low bioburden and strong compendial documentation.
• Reliable global supply.
• Regulatory support for DMF and change-control packages.

Reformulated migraine products

A 505(b)(2) product could target patients who do not obtain adequate relief from separate or sequential therapy. Commercial concepts include faster disintegration, lower pill burden, packaging for rescue use, and pediatric-appropriate administration.

The clinical proposition must be specific. "Better excipients" is not a market claim. "Faster tablet dispersion," "reduced swallowing burden," or "more stable performance under storage stress" can support a product strategy if linked to measurable patient or manufacturing outcomes.

Geographic expansion

Fixed-dose sumatriptan/naproxen products may have opportunities outside the United States, subject to local registration, patent status, and treatment guidelines. Market access analysis should examine:

• Whether the combination is approved in the target country.
• Local prescription and reimbursement rules.
• Availability of separate sumatriptan and naproxen products.
• National requirements for bioequivalence.
• Excipient restrictions.
• Local manufacturing incentives.
• Patent term and linkage rules.

A formulation that uses globally available excipients can reduce registration and supply-chain complexity.

How does Treximet compare with competing migraine products?

Product category	Main advantage	Excipient and commercial implication
Treximet or generic equivalent	One tablet combining triptan and NSAID	High active load and dissolution-management challenge
Sumatriptan alone	Lower tablet mass and simpler manufacturing	Less anti-inflammatory component; greater pill burden if naproxen is added separately
Separate sumatriptan plus naproxen	Dose flexibility	Two products and lower adherence convenience
Rizatriptan or other triptans	Alternative triptan pharmacology	Different active and excipient platform
CGRP receptor antagonists	Non-triptan mechanism and broader positioning	Higher-value branded or specialty products, often with different formulation economics
Nasal or injectable triptans	Useful when oral absorption is impaired	Device and manufacturing complexity
OTC analgesics	Low cost and broad access	Weaker migraine-specific positioning

Treximet’s main product advantage is convenience. Its main formulation disadvantage is the large tablet mass created by naproxen sodium. That tradeoff defines the commercial opportunity for excipient suppliers and reformulation developers.

What litigation, Paragraph IV, and settlement issues affect Treximet?

Paragraph IV risk historically centered on generic applicants asserting that listed patents were invalid, unenforceable, or not infringed. For a mature small-molecule combination, the litigation window is most commercially relevant before patent expiry and during first-filer eligibility.

The practical issues are:

• Which patents were listed for the reference product?
• Whether an ANDA applicant filed a Paragraph IV certification.
• Whether the patent holder sued within the statutory period.
• Whether a 30-month stay applied.
• Whether a settlement created a licensed entry date.
• Whether first-filer exclusivity delayed later generic approvals.

Historical litigation and settlement terms should be verified through FDA records, court dockets, and company filings. A settlement date is not equivalent to the earliest possible commercial launch date because manufacturing readiness, tentative approval, exclusivity, and regulatory deficiencies can alter timing.

How strong is the Treximet patent estate?

The legacy Treximet estate is commercially weaker than a current biologic or complex-delivery estate. The product uses known small molecules in an oral tablet, and its original approval dates to 2008. Any remaining protection is likely to be narrower and more vulnerable to design-around than protection covering a novel active ingredient.

The stronger barriers are practical rather than purely legal:

• Demonstrating bioequivalence for two actives in one tablet.
• Achieving consistent dissolution across batches.
• Controlling content uniformity for sumatriptan.
• Preventing scale-up failures.
• Maintaining stable supply of qualified excipients.
• Meeting FDA expectations for formulation changes.

These barriers can support margin and supply advantages, but they do not create the same exclusionary power as an unexpired composition-of-matter patent.

Key Takeaways

• Treximet combines 85 mg sumatriptan equivalent with 500 mg naproxen sodium in an immediate-release tablet.
• Its labeled excipients include croscarmellose sodium, microcrystalline cellulose, povidone, sodium bicarbonate, sodium lauryl sulfate, magnesium stearate, hypromellose, talc, titanium dioxide, and FD&C Blue No. 2 aluminum lake.
• The central formulation challenge is rapid, reproducible dissolution from a high-active-load tablet.
• Generic opportunities are strongest in cost-efficient manufacturing, excipient sourcing, and reliable bioequivalence.
• Reformulation opportunities include smaller tablets, rapidly disintegrating systems, dose flexibility, improved moisture stability, and pediatric-oriented products.
• A conventional ANDA is suitable for a bioequivalent immediate-release generic. A materially different delivery system may require a 505(b)(2) strategy.
• Patent value is likely to be narrower than the commercial value of manufacturing know-how and regulatory execution.
• Current Orange Book, patent, litigation, and settlement status should govern any launch or licensing decision.

Frequently Asked Questions

Can a generic Treximet use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product remains pharmaceutically equivalent and the differences do not affect safety, efficacy, or performance.

Is sodium bicarbonate essential to Treximet?

The FDA label identifies sodium bicarbonate as an inactive ingredient, but the label does not establish that it is indispensable. A generic applicant may replace it if the resulting product meets applicable regulatory and performance requirements.

Can Treximet be made as an orally disintegrating tablet?

Yes, technically, but the 500 mg naproxen sodium dose creates substantial tablet-mass and taste-masking challenges. The product would likely require differentiated development rather than a simple generic substitution.

Are Treximet excipients individually patentable?

Individual established excipients generally provide limited protection. Patent value is more likely to arise from a novel combination, concentration range, manufacturing process, release profile, or dosage form supported by comparative data.

What is the most attractive commercial opportunity around Treximet?

For near-term revenue, supplying qualified excipients or manufacturing generic immediate-release tablets is more predictable than launching a novel reformulation. Higher upside may exist in a rapidly disintegrating or dose-flexible product, but that strategy requires greater regulatory and clinical investment.

References

1. U.S. Food and Drug Administration. (2008). Treximet (sumatriptan and naproxen sodium) prescribing information.
2. U.S. Food and Drug Administration. (2022). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs, Treximet.
4. U.S. Patent and Trademark Office. (n.d.). Patent Center.